Furthermore, there was a significant decrease in the ratio of Th1:Tregs, Th17:Tregs, and CD4+GM-CSF+:Tregs, suggesting a shift in the T cell profile towards anti-inflammatory phenotypes, plausibly able to effectively regulate potentially pathogenic CD4+ T cells in MS (66). The gene discussed is CSF2; the disease is myeloid sarcoma.